Drug news

NICE recommends Eylea (aflibercept) for DMO- Bayer HealthCare

Read time: 1 mins

Last updated:21st Feb 2015

Published:21st Feb 2015

Source: Pharmawand

The UK's National Institute for Health and Care Excellence (NICE) has recommended Eylea (aflibercept ophthalmic solution) from Bayer HealthCare for treatment of diabetic macular oedema (DMO).The recommendation relates to patients who have a central retinal thickness of 400 micrometres or more at the start of treatment. Bayer has agreed to a patient access scheme and a discount. Final NICE guidance is expected in June 2015.

Comment: Early stage DMO patients are not covered by the recommendation and they may have to rely on laser therapy. The drug has a competitor which is Lucentis (ranibizumab) which was NICE recommended for DMO in April 2013.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Safety of switching from a Vitamin K antagonist to a non–Vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation.

FRAIL-AF trial investigators set out to study the question of whether frail, elderly patients with atrial fibrillation who were doing well with vitamin K antagonists (VKA) should be switched to direct-acting oral anticoagulants (DOAC).

1 mins

Drug news

FDA approves updated Lupkynis (voclosporin) label to include long term data from the Aurora Clinical Program.-- Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals Inc. announced that the FDA has approved a label update for Lupkynis. The updated label no longer includes language indicating that the safety and efficacy of Lupkynis has not been established beyond one year.

3 min

Drug news

Phase III KEYNOTE-811 trial met dual primary endpoint of overall survival (OS) as first-line treatment in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.- Merck Inc.,

Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival (OS) for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

1 min

See all news